Daratumumab, a CD38 antibody is also being assessed as a potential disease-modifying strategy in AD since CD38 also modulates microglial activation and has been shown to enhance Aβ accumulation (Blacher et al., 2015). Here, CD38 is linked to Alzheimer disease.